Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 202

Sort by

Sort Order Select

Journal Articles

Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration

Blood (2023) 142 (Supplement 1): 71.

https://doi.org/10.1182/blood-2023-178815

Published: 2023

Journal Articles

Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study

Blood (2023) 142 (Supplement 1): 170.

https://doi.org/10.1182/blood-2023-178030

Published: 2023

Journal Articles

Plasma Circulating Tumor DNA (ctDNA) as an Alternative to Tissue DNA for Genotyping of DLBCL: Results from the POLARIX Study

Fabrice Jardin, Vibha Raghavan, Samuel Tracy, Sandhya Balasubramanian, Laurie H. Sehn, Christopher R. Flowers, Franck Morschhauser, Alex F. Herrera, Marek Trněný, Jeff P. Sharman, Gilles Salles, Hervé Tilly, Jonathan W. Friedberg, Will Harris, Jamie H. Hirata, Calvin Lee, Yanwen Jiang, Georg Lenz

Blood (2023) 142 (Supplement 1): 169.

https://doi.org/10.1182/blood-2023-178564

Published: 2023

Journal Articles

Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study

Blood (2023) 142 (Supplement 1): 3000.

https://doi.org/10.1182/blood-2023-178623

Published: 2023

Journal Articles

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Blood (2023) 142 (Supplement 1): 3074.

https://doi.org/10.1182/blood-2023-184933

Published: 2023

Journal Articles

Early Results Indicate Acceptable Safety and Promising Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

Andrew D. Zelenetz, Catherine S. Diefenbach, Charles Herbaux, Monica Tani, Roch Houot, Mariana Bastos-Oreiro, Herve Tilly, Thomas Gastinne, Catherine Thieblemont, Ethan Troy-Barnes, Stefano Olivieri, Murali Kesavan, Manisha Kanwar, Simona Barlera, Katerina Hatzi, Yanwen Jiang, Michelle Boyer, Franck Morschhauser

Blood (2023) 142 (Supplement 1): 439.

https://doi.org/10.1182/blood-2023-174855

Published: 2023

Journal Articles

R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

Blood (2023) 142 (Supplement 1): 435.

https://doi.org/10.1182/blood-2023-172951

Published: 2023

Journal Articles

A Simplified IPI Including BCL2 Identifies IPI 3 Patients with Poor Prognosis - a GLA/ Dshnhl and Lysa Collaboration

Blood (2023) 142 (Supplement 1): 191.

https://doi.org/10.1182/blood-2023-184611

Published: 2023

Journal Articles

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Blood (2023) 142 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2023-179887

Published: 2023

Journal Articles

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Blood (2023) 142 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2023-188896

Published: 2023

Journal Articles

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Blood (2023) 141 (16): 1971–1981.

https://doi.org/10.1182/blood.2022017734

Published: 2023

Includes: Supplemental data

Journal Articles

Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial

Eva Hoster, Marie-Helene Delfau, Elizabeth A. Macintyre, Linmiao Jiang, Stephan Stilgenbauer, Ursula Vehling-Kaiser, Gilles Salles, Catherine Thieblemont, Hervé Tilly, Lothar Kanz, Pierre Feugier, Kai Huebel, Christian Schmidt, Vincent Ribrag, Hanneke Kluin-Nelemans, Martin Dreyling, Christiane Pott

Blood (2022) 140 (Supplement 1): 1304–1306.

https://doi.org/10.1182/blood-2022-159932

Published: 2022

Journal Articles

Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study

Blood (2022) 140 (Supplement 1): 1297–1300.

https://doi.org/10.1182/blood-2022-157559

Published: 2022

Journal Articles

Sub-Cutaneous Administration of Rituximab Triggers a Pro-Phagocytic Phenotype of Monocytic Compartment in Low-Tumor Burden Follicular Lymphoma Patients Included in the Flirt Clinical Trial, a Lysa Study

Mikael Roussel, Cedric Menard, Delphine Rossille, Julien Saint-Vanne, Joelle Dulong, Emmanuel Bachy, Herve Tilly, Delphine Pranger, Franck Morschhauser, Luc Xerri, Guillaume Cartron, Karin Tarte

Blood (2022) 140 (Supplement 1): 6462–6463.

https://doi.org/10.1182/blood-2022-169295

Published: 2022

Journal Articles

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

Blood (2022) 140 (Supplement 1): 9470–9472.

https://doi.org/10.1182/blood-2022-159586

Published: 2022

Journal Articles

Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Final Results of 18 Patients Treated at RP2D of Selinexor in the Selinda Phase Ib Lysa Study

Marie Maerevoet, Olivier Casasnovas, Guillaume Cartron, Franck Morschhauser, Catherine Thieblemont, Kamal Bouabdallah, Pierre Feugier, Vanessa Szablewski, Stéphanie Becker, Hervé Tilly

Blood (2022) 140 (Supplement 1): 6621–6622.

https://doi.org/10.1182/blood-2022-157496

Published: 2022

Journal Articles

Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study

Anne Ségolène Cottereau, Louis Rebaud, Judith Trotman, Pierre Feugier, Loretta J. Nastoupil, Emmanuel Bachy, Ian W. Flinn, Corinne Haioun, Loic Ysebaert, Nancy L. Bartlett, Hervé Tilly, René-Olivier Casasnovas, Romain Ricci, Cedric Portugues, Irène Buvat, Michel Meignan, Franck Morschhauser

Blood (2022) 140 (Supplement 1): 6474–6476.

https://doi.org/10.1182/blood-2022-159207

Published: 2022

Journal Articles

The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK-Positive ALCL Treated By CHOEP: A Lysa Study

Blood (2022) 140 (Supplement 1): 3680–3682.

https://doi.org/10.1182/blood-2022-170841

Published: 2022

Journal Articles

Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study

Frédéric Boissard, Hervé Tilly, Georg Lenz, Graham P. Collins, Antonio Pinto, Laurie H. Sehn, Gilles Salles, Mathilde Roussel, Leonardo Simonella, Rodrigo Ho, Jamie Hirata, Calvin Lee, Anthony Masaquel, Aino Launonen

Blood (2022) 140 (Supplement 1): 6645–6647.

https://doi.org/10.1182/blood-2022-157904

Published: 2022

Journal Articles

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study

Blood (2022) 139 (15): 2338–2346.

https://doi.org/10.1182/blood.2021013526

Published: 2022

Includes: Supplemental data

NARROW

Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration

Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study

Plasma Circulating Tumor DNA (ctDNA) as an Alternative to Tissue DNA for Genotyping of DLBCL: Results from the POLARIX Study

Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Early Results Indicate Acceptable Safety and Promising Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

A Simplified IPI Including BCL2 Identifies IPI 3 Patients with Poor Prognosis - a GLA/ Dshnhl and Lysa Collaboration

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial

Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study

Sub-Cutaneous Administration of Rituximab Triggers a Pro-Phagocytic Phenotype of Monocytic Compartment in Low-Tumor Burden Follicular Lymphoma Patients Included in the Flirt Clinical Trial, a Lysa Study

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Final Results of 18 Patients Treated at RP2D of Selinexor in the Selinda Phase Ib Lysa Study

Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study

The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK-Positive ALCL Treated By CHOEP: A Lysa Study

Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only